De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Laboratorios Farmaceuticos Rovi Dividend
Dividend criteriumcontroles 2/6
Laboratorios Farmaceuticos Rovi is een dividendbetalend bedrijf met een huidig rendement van 1.55% dat ruimschoots wordt gedekt door de winst.
Belangrijke informatie
1.5%
Dividendrendement
39%
Uitbetalingsratio
| Gemiddelde opbrengst industrie | 2.3% |
| Volgende betaaldatum dividend | n/a |
| Ex-dividenddatum | n/a |
| Dividend per aandeel | €1.104 |
| Winst per aandeel | €2.89 |
| Dividendrendementsvoorspelling | 2.3% |
Recente dividendupdates
Recent updates
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Aug 29
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Jul 15We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet
Jun 17Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
May 08These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Apr 17Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Feb 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Dec 21Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Nov 03Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Aug 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jul 14Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
May 26Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
May 05Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Apr 11Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Feb 22An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
Dec 10These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Nov 04Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
Sep 15Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Aug 28Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Jun 15I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease
Feb 13Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Jan 02A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Dec 12Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Nov 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Sep 24Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Jun 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Apr 06Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%
Mar 15If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late
Feb 16
Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?
Jan 26These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Jan 04Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years
Dec 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?
Nov 26Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: De dividendbetalingen van ROVI zijn de afgelopen 10 jaar volatiel geweest.
Groeiend dividend: De dividendbetalingen van ROVI zijn de afgelopen 10 jaar gestegen.
Dividendrendement versus markt
| Laboratorios Farmaceuticos Rovi Dividendrendement versus markt |
|---|
| Segment | Dividendrendement |
|---|---|
| Bedrijf (ROVI) | 1.5% |
| Markt onderkant 25% (ES) | 2.4% |
| Markt Top 25% (ES) | 5.4% |
| Gemiddelde industrie (Pharmaceuticals) | 2.3% |
| Analist prognose (ROVI) (tot 3 jaar) | 2.3% |
Opmerkelijk dividend: Het dividend van ROVI ( 1.55% ) is niet noemenswaardig vergeleken met de onderste 25% van de dividendbetalers op de Spanish markt ( 2.38% ).
Hoog dividend: Het dividend ROVI ( 1.55% ) is laag vergeleken met de top 25% van dividendbetalers in de Spanish markt ( 5.41% ).
Winstuitkering aan aandeelhouders
Verdiendekking: Met zijn redelijk lage payout ratio ( 38.9% ) worden de dividendbetalingen van ROVI ruimschoots gedekt door de winst.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: Gezien de hoge cash payout ratio ( 162.4% ) worden de dividendbetalingen van ROVI niet goed gedekt door de kasstromen.